Nephrology Medical News about Tacrolimus, Lupus nephritis, Glucocorticoid

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study
Modern Rheumatology, 08/24/09

Miyasaka N et al. – In patients on glucocorticoid therapy for lupus nephritis, addition of tacrolimus to basal therapy achieved significant improvement; tacrolimus may therefore be a useful alternative treatment for lupus nephritis.

Methods

An evaluation of the efficacy and safety of tacrolimus in pts receiving glucocorticoid therapy for lupus nephritis
Patients with persistent nephritis randomized to receive 28 wks of double-blind treatment with tacrolimus (3 mg/d) or placebo
Primary endpoint: change in the lupus nephritis disease activity index (LNDAI) calculated from scores for-
- Daily urinary protein excretion
- Urinary red cells
- Serum creatinine
- Anti-double-stranded DNA antibody, and
- Serum complement
Statistical analysis was performed using the full analysis set

Results

The LNDAI was decreased by 32.9% in the tacrolimus group (n=28) and was increased by 2.3% in the placebo group (n=35) at final evaluation
There was significant improvement in the tacrolimus group
Daily urinary protein excretion showed a significant decrease in the tacrolimus group
The complement (C3) level showed a significant increase in the tacrolimus group
Treatment-related AEs occurred in 92.9% of the tacrolimus group and 80.0% of the placebo group, but the difference was not significant

<< Previous
Mayer-Rokitansky-Kuster-Hauser Syndrome Associated with a...

Next >>
Beta-Catenin Promotes Survival of Renal Epithelial Cells by...

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09 Relevance Score: 69%

Biomarkers for Lupus Nephritis: The Quest Continues
Clinical Journal of the American Society of Nephrology, 11/13/09 Relevance Score: 68%

Pulmonary and psoas muscle nocardiosis in a patient with lupus nephritis: a case report and review of the literature
Rheumatology International, 11/13/09 Relevance Score: 67%

Male gender results in more severe lupus nephritis
Rheumatology International, 10/05/09 Relevance Score: 67%

Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus
Modern Rheumatology, 10/22/09 Relevance Score: 66%